

▪ 2012 ▪

25th Annual Meeting




May 9–12, 2012

New Orleans, LA  Hilton New Orleans Riverside



The 25th Annual Meeting will offer pediatric hematologists/oncologists a concentrated and high-quality continuing medical education (CME) program, covering a broad spectrum of clinical topics and a growing program of original science presentations. In addition to presenting the latest clinical discoveries, the meeting offers you an opportunity to network with colleagues, acquire new skills, meet experts, and advance your career to the next level.

The 2012 meeting will feature

- ◆ the Presidential Symposium on Ethical Dilemmas
- ◆ a joint ASPHO and Pediatric Blood and Marrow Transplant Consortium lunch symposium
- ◆ eleven symposia and eight workshops
- ◆ Young Investigator sessions, including a workshop on research careers and a symposium on oral presentation skills and mentorship 
- ◆ five platform sessions
- ◆ celebration of the 25th Annual Meeting.

Objectives

- ◆ Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- ◆ Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- ◆ Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.

CME Credit

The ASPHO 25th Annual Meeting will offer CME credit. Credit will be awarded for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation.

ASPHO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASPHO designates this live activity for a maximum of 23.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASPHO offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting the ASPHO website, ASPHOMeeting.org, and clicking on the Evaluation Form link located on the home page. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their continuing education certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation regardless of whether they are seeking CME credits. For more information, visit ASPHOMeeting.org or call 847.375.4716.

Disclosure

It is the policy of ASPHO that the planners, faculty, and providers disclose the existence of any significant financial interests or other relationships they and/or their spouse/partner may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Program Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information will be published in course materials. Learners will also be informed when no relevant financial relationships exist.

Disclaimer

The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

Abstracts and DVDs

Registrants can access and view abstracts online prior to the meeting by visiting www.aspho.org.

ASPHO will offer Annual Meeting attendees session recordings on DVD. Conference attendees will have the opportunity to purchase a DVD when they register for the meeting or in New Orleans, May 9–12, 2012, at a special discounted rate of \$45. After May 13, DVDs will be sold for \$250 to members and \$350 to nonmembers.

With these DVDs, you will have convenient access to session recordings without long downloads or access codes. Take advantage of this special limited offer when you register or in New Orleans.



Schedule at a Glance

Wednesday, May 9

1 pm

Registration Open

(S02) Immunodeficiencies

(W02) Problem Cases: Challenging Niches Within Pediatric Hematology

3–5 pm

Symposia

(S01) Keeping an Eye on Retinoblastoma—An Update on Retinoblastoma Biology and Therapy

5:30–7 pm

Concurrent Workshops

(W01) Melanoma—A Primer for the Pediatric Oncologist

7:15–8:45 pm

Corporate Forum Dinner Symposium


Division Directors Meeting

Advance registration is required.

Thursday, May 10

7:30–9 am

Concurrent Workshops

(W03) Young Investigator Workshop: A Research Career Starter—ASPHO Style 

(W04) Relapsed ALL: Current Therapeutic Options

9–11 am


Presidential Symposium

(S03) Ethical Dilemmas in Pediatric Hematology/Oncology

11:30 am–12:30 pm

Concurrent Platform Sessions I

12:45–2:15 pm

(L01) One-on-One Young Investigator Career Workshop Lunch 

Advance registration is required.

(L02) Novel Reduced Toxicity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation in Children with Benign Hematological Disorders: Improved Outcomes and Expanded Indications

Advance registration is required.


2:30–4:30 pm

Symposia

(S04) Young Investigator Symposium 

(S05) Update on Pediatric Cancer Predisposition Syndromes

4:45–5:45 pm

Young Investigator Award Presentations 

Plenary Platform Session

5:45–6:45 pm

Author-Attended Poster Session A

Odd-numbered posters

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium

Fellowship Program Directors Meeting

Advance registration is required.

Friday, May 11

6:30–8 am

Breakfast in the Exhibit Hall

6:30–9:45 am

Exhibits Open

7:30–9 am

Concurrent Workshops

(W05) Developing a Best Practice for Chemotherapy Ordering

(W06) Reproductive Issues in Blood Disorders in Women and Girls: Cancer and Sickle Cell Disease

9:30–11:30 am

Symposia

(S06) Epigenetic Reprogramming to Reverse Chemoresistance in Childhood ALL

(S07) The Tipping Point: Iron-Restricted Anemias and Iron Overload Disorders

11:30 am–1 pm

Concurrent Workshops

(W07) Thromboprophylaxis: Who, When, Why, How?

(W08) Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Children Are Not Little Adults

11:30 am–2 pm

Exhibits Open

1–2 pm

Lunch in Exhibit Hall

2–4 pm

Symposia

(S08) What Is New in Platelets?

(S09) Current Concepts in Ependymoma: From Biology to Clinical Care

4:15–6:15 pm

Business Meeting and Award Presentation

- ◆ President's Remarks
- ◆ Frank A. Oski Memorial Lecture
- ◆ Distinguished Career Award

6:15–7:15 pm

Author-Attended Poster Session B

Even-numbered posters

6:15–7:30 pm

Reception with Exhibits and Posters

7:45–8:45 pm

25th Annual Meeting Anniversary Session

Saturday, May 12

8–9 am

Concurrent Platform Sessions II


9:15–11:15 am

Symposia

(S10) Rare Cancers in Children and Adolescents

(S11) Bone Marrow Failure: Emerging Clinical and Molecular Themes

*For more information on corporate forum symposia, see page 12.



Wednesday, May 9**3–5 pm****Symposia****(S01) Keeping an Eye on Retinoblastoma—An Update on Retinoblastoma Biology and Therapy***Moderator: Rima Jubran, MD*

The approach to treating retinoblastoma is changing, with new insights into retinoblastoma biology leading to novel, targeted therapeutic approaches. This symposium will provide cutting-edge updates on

- ♦ advances in the biology of retinoblastoma
- ♦ recent Children's Oncology Group (COG) retinoblastoma clinical trial results
- ♦ novel local control approaches for retinoblastoma
- ♦ genetic counseling for retinoblastoma.

The audience will develop a better understanding of the biology of retinoblastoma, recognizing that "it's not just the Rb gene." Furthermore, attendees will gain familiarity with recent COG trials and new therapeutic approaches that may be used to preserve vision and avoid enucleation and exposure to radiation. Finally, an update on new considerations important in retinoblastoma genetic counseling will be provided.

Advances in the Biology of Retinoblastoma*Michael A. Dyer, PhD***COG Retinoblastoma Clinical Trials***Murali M. Chintagumpala, MD***What's New in Local Control?***Linn Murphree, MD***New Considerations in Genetic Counseling for Retinoblastoma***Brenda L. Gallie, MD***(S02) Immunodeficiencies***Moderator: Sinisa Dovat, MD PhD*

Advances in diagnostic and treatment options have resulted in improved survival of patients with immunodeficiencies. To make optimal treatment decisions for immunodeficiencies, pediatric hematologists/oncologists must have knowledge of disease mechanisms, state-of-the-art diagnostic tests, and therapeutic modalities. The diagnosis and treatment of primary and acquired immunodeficiencies are challenging problems for pediatric hematologists/oncologists. Early diagnosis is essential for initiation of optimal treatment. Recent advances in diagnostic tools, disease classification, and novel therapeutic modalities have resulted in significantly improved survival. However, these require continuous education of physicians to provide patients with the best treatment (*J Allergy Clin Immunol* 2010, 125:S182-94). The paucity of these patients makes clinical learning experiences for this type of disease particularly challenging.

Introduction*Sinisa Dovat, MD PhD***Gene Therapy for Immunodeficiency: Current Status and Challenges***Sung-Yun Pai, MD***Prospective on Laboratory Diagnosis and Hematopoietic Stem Cell Transplantation for Immunodeficiencies***Hisbam M. Abdel-Azim, MD***Pathophysiology and Biomarkers of Immune Deficiency***Kimberly J. Payne, PhD***5:30–7 pm****Concurrent Workshops****(W01) Melanoma—A Primer for the Pediatric Oncologist***Moderators: Leo Mascarenhas, MD MS; Dennis P. Hughes, MD PhD*

Melanoma is an adult cancer that is rare in pediatrics and is often managed by surgeons and dermatologists. There are fewer than 800 cases of melanoma in individuals younger than 20 years of age in the United States annually, accounting for >5% of cancer in teens and 3% of all childhood cancers, and it has the highest increasing incidence in the adolescent and young adult age group. The incidence of pediatric melanoma increased 46% per year of age and 2.9% per year from 1973 to 2001. In addition to a lack of awareness and diverse points of entry into care, there is often a delay in diagnosis that can result in improper early management, missed opportunities for patient and family education, and advanced disease, which can lead to a reduced probability of survival and poorer quality of life. This workshop will provide an overview of pediatric melanoma epidemiology, management, and follow-up care and highlight recent advances in drug therapy for melanoma with molecular-targeted and immune-based therapies (extrapolating information from the adult experience to young patients). Attendees will have a higher index of suspicion for melanoma and learn an evidence-based approach for the management of these patients.

Introduction*Leo Mascarenhas, MD MS***Epidemiology of Childhood Melanoma***John J. Strouse, MD PhD***Staging and Surgical Management***Mary Austin, MD MPH***Pathology Essentials***Raymond Barnhill, MD***Results from Seminal Melanoma Clinical Trials in Adults***Michael K. Wong, MD PhD FRCPC***Pediatric Perspective and Cases***Dennis P. Hughes, MD PhD***Panelist***Fariba Navid, MD*

This workshop is supported in part by the Pablove Foundation.

(W02) Problem Cases: Challenging Niches Within Pediatric Hematology

Moderator: *Donald L. Yee, MD*

Clinical hematology teems with problem cases that extend beyond what is covered in subspecialty training, up-to-date content review courses, or even focused state-of-the-art review articles. The specific topics in this workshop are among the areas of need and requested emphasis for increased learning opportunities cited by surveys of recent ASPHO Annual Meeting attendees. Patients with chronic idiopathic thrombocytopenic purpura frequently present vexing clinical challenges given the often refractory clinical course. Newly approved agents provide alternatives to varied immunomodulatory approaches used over the years, but pediatric experience with the former is limited. “Abnormal” hemoglobins are a common basis for hematologic consultation, yet the large number of possible variants and the relative infrequency of encountering a particular variant can lead to low comfort levels within our subspecialty. Finally, von Willebrand factor testing, discrepant hemophilia, and artifactual causes of coagulation lab abnormalities pose important challenges that can often be overcome via a strong hematologist-pathologist interface.

Introduction

Donald L. Yee, MD

Approach to the Patient with Chronic, Refractory ITP

Jenny M. Despotovic, DO MS

“Abnormal” Hemoglobin Variants: When (and When Not) to Worry

Gladstone Airewele, MD MPH

Pitfalls in the Coagulation Lab: Dialogue with the Pathologist

Shiu-Ki R. Hui, MD

7:15–8:45 pm

Corporate Forum Dinner Symposium

Advance registration is required. For further information, please see page 12.

Division Directors Dinner Meeting

Advance registration is required.

Thursday, May 10

6:30–7:30 am

Continental Breakfast

7:30–9 am

Concurrent Workshops

(W03) Young Investigator Workshop: A Research Career Starter—ASPHO Style

Moderator: *Sarah R. Vaiselbub, MD*

One of ASPHO’s goals is to promote education for the pediatric hematologists/oncologists of the future. To guide young investigators on this mission, it is important to identify their research niche. This ASPHO workshop will highlight the path toward finding that niche as a foundation for an independent career.

In part 1 of this workshop Theodore Johnson and Betty Pace will present “Basic Science Research: Obstacles and Challenges

in Starting a New Lab,” during which they will explain the process of transitioning into the role of principal investigator and starting up a new research laboratory. Topics will include space and facilities usage, navigating safety and regulatory requirements, purchasing supplies and equipment, hiring personnel, ensuring data integrity, disseminating results, and identifying mentorship.

During part 2 of this workshop, Amanda Brandow will discuss establishing a career in patient-oriented research. This module illustrates the transition into an independent clinical researcher.

A panel discussion will be held during the third portion of the workshop. Junior and senior faculty will discuss their perspectives and experiences with the audience.

Basic Science Research: Obstacles and Challenges in Starting a New Lab

Theodore Johnson, MD PhD; Betty S. Pace, MD

Clinical Research: Establishing a Career in Patient-Oriented Research

Amanda M. Brandow, DO MS

(W04) Relapsed ALL: Current Therapeutic Options

Moderator: *Patrick A. Zweidler-McKay, MD PhD*

Relapsed acute lymphoblastic leukemia (ALL) is an all too common reality in pediatric oncology practice. Recent trials have shed new light on our successes and failures in first and second relapse. Improved use of cytotoxics and new targeted therapies continue to provide increasing options for these patients. This workshop will include didactic case studies to provide up-to-date information on the results of recent trials, current treatment options, and future trials in development.

Introduction to Relapsed ALL

Patrick A. Zweidler-McKay, MD PhD

First Relapse of ALL: The European Approach

Vaskar Saba, MD PhD MKBBS DCH FRCP FRCPath

First Relapse of ALL: The North American Approach

James A. Whitlock, MD

Second Relapse of ALL: Promising Therapies

Alan S. Wayne, MD

Case Presentations

Kara Davis, MD

9–11 am

Presidential Symposium

(S03) Ethical Dilemmas in Pediatric Hematology/Oncology

Moderator: *Jeffrey M. Lipton, MD PhD*

Pediatric hematologists/oncologists routinely encounter ethical dilemmas in their work, yet few clinicians in our field have frequent opportunities to develop new knowledge and skills in medical ethics. Time constraints and competing educational demands conspire to limit pediatric hematologists’/oncologists’ abilities to continually learn ethics on their own. This session will work to fill this educational gap by examining several key ethical dilemmas

relevant to our work in pediatric hematology/oncology. The symposium will serve as an ethics update to teach the audience about new and evolving ethics questions. The aim will be to enlighten the audience about current dilemmas in our field and to help learners develop an initial approach to ethical reasoning about these dilemmas.

A New Spin on an Old Challenge: The Impact of Social Networking on Medical Professionalism

Jennifer C. Kesselheim, MD MEd

Adolescent Patients' Refusals of Recommended Medical Care

Douglas S. Diekema, MD MPH

Return of Research Results to Clinical Trial Participants

Conrad V. Fernandez, MD FRCPC

11:30 am–12:30 pm

Concurrent Platform Sessions I

12:45–2:15 pm

(L01) One-on-One Young Investigator Career Workshop Lunch

Moderators: Douglas K. Grabam, MD PhD; Caroline A. Hastings, MD

Fellows and young investigators (YIs) will have an opportunity to meet with a leader in the field of pediatric hematology/oncology. Two experts in the following fields will be available for career discussions: clinical research—hematology, clinical research—oncology, basic science/translational research, health services/late effects, and clinician/educator. A special interest table will be available for issues specific to foreign medical graduates. The purpose of this luncheon is to allow fellows and junior faculty to discuss issues one on one with leaders in the field or ask questions related to career development in a small group setting. One to two discussion leaders will be placed at each luncheon table. After 30 minutes of discussion, the YI participants will be invited to consider switching to a different table for further discussion. *Advance registration is required.*

(LCH) Clinical Research: Hematology

Zora R. Rogers, MD; Guy Young, MD

(LCO) Clinical Research: Oncology

James Feusner, MD; William G. Woods, MD; William L. Carroll, MD

(LBT) Basic Science/Translational Research

Kathleen Sakamoto, MD PhD; Douglas K. Grabam, MD PhD; Daniel S. Wechsler, MD PhD

(LCS) Health Services/Late Effects

Joseph P. Neglia, MD MPH

(LCE) Clinician/Educator

Joanne Hilden, MD; Caroline A. Hastings, MD

(FMG) Foreign Medical Graduates

Sarah R. Vaiselbub, MD

(L02) Novel Reduced Toxicity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation in Children with Benign Hematological Disorders: Improved Outcomes and Expanded Indications

Moderator: Mitchell S. Cairo, MD

The prognosis and cure for several pediatric nonmalignant diseases such as hemophagocytic lymphohistiocytosis (HLH), sickle cell disease (SCD), and severe aplastic anemia (SAA) have been dramatically improved with myeloablative conditioning and human leukocyte antigen (HLA)-matched sibling allogeneic stem cell transplantation. However, this approach is limited by numerous factors including treatment-related mortality (TRM), late effects such as infertility and malignancy, and limited number of available allogeneic stem cell donors. Advances in utilizing reduced toxicity conditioning prior to allogeneic stem cell transplantation and the use of alternative allogeneic stem cell donor sources such as HLA-matched unrelated donors, unrelated cord blood units, and familial haploidentical donors in these specific pediatric hematological diseases have occurred during the past several years. During this educational session the current status of reduced toxicity conditioning and the use of alternative allogeneic donors in children with HLH, SCD, and SAA will be presented and discussed. *Advance registration is required.*

Introduction

Mitchell S. Cairo, MD

Alentuzumab-Based Reduced Toxicity Regimens Prior to Allogeneic Stem Cell Transplantation in Children with HLH: Improved Survival

Lisa Filipovich, MD

Allogeneic Stem Cell Transplantation in Children with Hemoglobinopathies: Reducing the Therapy and Toxicity of Conditioning Regimens

Shalini Shenoy, MD

Improved Outcome Following Unrelated Donor Allografts: When Should Unrelated Donor Allografts Be Offered to Children with Severe Aplastic Anemia?

Michael A. Pulsipher, MD

This luncheon symposium is supported by the Pediatric Blood and Marrow Transplant Consortium.

2:30–4:30 pm

Symposia

(S04) Young Investigator Symposium

Moderators: Caroline A. Hastings, MD; Emily Riehm Meier, MD

To have a successful and rewarding career, pediatric hematologists/oncologists must possess a diverse skill set. This symposium will provide tools that will ensure continued career success. Effective oral presentation skills will be reviewed, highlighting the appropriate use of audiovisual materials during lectures. The symposium will then shift focus to mentorship, first addressing how fellows can be proactive in receiving critical feedback on their research projects through their Scholarship Oversight Committee. Finally, ASPHO's mentorship program will be unveiled. This program will provide early-career pediatric hematologists/oncologists the opportunity to receive mentoring from senior ASPHO members in clinical, research, and clinician

educator pathways. The goal of the mentorship program is to supplement existing mentoring by offering new networking opportunities and exposure to academic areas not currently represented at the mentee's institution.

How to Give an Effective Oral Presentation

Guy Young, MD

The Scholarship Oversight Committee: What Does the American Board of Pediatrics Want and How Can Fellows Benefit from the Experience?

Caroline A. Hastings, MD

Launching the ASPHO Mentorship Program

Sarah R. Vaiselbub, MD

(S05) Update on Pediatric Cancer Predisposition Syndromes

Moderator: Joshua D. Schiffman, MD

During the past 5–10 years there has been great progress in the field of pediatric genetic predisposition syndromes. These syndromes span the field of pediatric hematology and oncology, and thus knowledge is needed for the general practitioner and the specialist in this area (*Cancer Genetics* 2011 May: 204; *Blood Reviews* 2010 May: 24; *J Pediatr Hematol Oncol* 2010 April: 32). This area is also important to other pediatric subspecialties such as gastroenterology, dermatology, surgery, neurology, and general pediatrics. As the specific genetic abnormalities are identified for these syndromes, keener awareness is needed for surveillance and screening. It has also become clear that the practitioner must understand the psychological impact of these diagnoses as it relates to their patients and families.

Introduction

Joshua D. Schiffman, MD

Identifying Hereditary Pediatric Cancer Syndromes as They Relate to the Pediatric Hematologist/Oncologist

James I. Geller, MD FAAP

All You Need to Know About Screening and Surveillance

Erin A. Mundt, MS CGC

Exploring the Ethical Issues in Pediatric Cancer Syndromes

John A. Robertson, JD

A Family's Insight

Li-Fraumeni Family

This symposium is supported in part by the High Risk Cancer Research Program at Huntsman Cancer Institute (University of Utah).

4:45–5:45 pm

Young Investigator Award Presentations

Plenary Platform Session

5:45–6:45 pm

Author-Attended Poster Session A

Odd-numbered posters

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium

Advance registration is required. For further information, please see page 12.

Fellowship Program Directors' Dinner Meeting

Advance registration is required.

Friday, May 11

6:30–8 am

Breakfast in Exhibit Hall

6:30–9:45 am

Exhibits Open

7:30–9 am

Concurrent Workshops

(W05) Developing a Best Practice for Chemotherapy Ordering

Moderator: Brigitta U. Mueller, MD MHCM

Many pediatric hematology/oncology practices struggle with the development of practice guidelines and procedures for ensuring safe ordering of chemotherapy. Many factors contribute to identifying best practice guidelines and procedures, such as type of institution, medication ordering by paper or electronic methods, the development of checking chemotherapy accuracy and dosing, training programs, and the number of verification steps. This workshop will report on the current variability in chemotherapy ordering practices at various pediatric institutions. The basic components of safe chemotherapy ordering, as well as the current American Society of Clinical Oncology/Oncology Nursing Society (ASCO/ONS) Standards, will be reviewed. Finally, a panel will present current research in this area and discuss the challenges at the different types of institutions.

Chemotherapy Ordering Practices: Results of ASPHO Practice Committee Survey

Michael R. Jeng, MD

Key Components to Ensure Safe Chemotherapy Ordering

Brigitta U. Mueller, MD MHCM

Panel Discussion and Update on Current Practices

Amy L. Billett, MD

(W06) Reproductive Issues in Blood Disorders in Women and Girls: Cancer and Sickle Cell Disease

Moderator: Roshni Kulkarni, MD

Women and adolescent girls with blood disorders encounter serious challenges during the reproductive life stage. Healthcare providers need to understand optimal management and treatment methods to enhance the quality of life of these patients, specifically with cancer and sickle cell disease. Examples of reproductive life-stage concerns for women with cancer are ovarian failure and infertility, common side effects of chemotherapy. With proper training in treatment options and patient communication, there are cases in which physicians can provide appropriate care to improve fertility. All patients can be better counseled to understand the full effects of chemotherapy and pregnancy outcomes. A

major issue for women with sickle cell disease is childbearing and severe pregnancy-related complications including preeclampsia, eclampsia, preterm labor, and placental abruption. Providers need education to prepare for and manage these complications. In addition, communicating the full range of genetic options available to patients can reduce adverse pregnancy outcomes.

Reproductive Issues in Cancer

Charles A. Sklar, MD

Reproductive Issues in Sickle Cell Disease

Alexis A. Thompson, MD MPH

Panelists

Kristin Nunez, MS; Kim Smith-Whitley, MD

This workshop is supported in part by the Foundation for Women & Girls with Blood Disorders.

9:30–11:30 am

Symposia

(S06) Epigenetic Reprogramming to Reverse Chemoresistance in Childhood ALL

Moderator: Douglas K. Graham, MD PhD

There is emerging evidence that both *de novo* and acquired chemotherapy resistance in childhood acute lymphoblastic leukemia (ALL) is caused by aberrant epigenetic programming via gene promoter methylation and chromatin histone protein modifications. Importantly, these processes are potentially targetable using clinically available drugs (DNA methyltransferase inhibitors and histone deacetylase inhibitors), and clinical trials are under way. The objectives of this seminar are to inform the audience of the rationale behind the clinical development of epigenetically targeted treatment strategies in childhood ALL and to make the audience aware of the opportunities available for patients to participate in ongoing and planned clinical trials.

Molecularly targeted therapeutics are increasingly being incorporated into treatment strategies for childhood cancer in general, and for leukemia in particular. Practitioners will benefit from staying up to date on cutting-edge translational and clinical research that will transform the standard of care over the next several years.

The Role of Epigenetics in High-Risk Childhood

ALL: Epigenetics as a Modifiable Cause of *De Novo* Chemoresistance

Patrick Brown, MD

The Role of Epigenetics in Relapsed Childhood

ALL: Epigenetics as a Modifiable Cause of Acquired Chemoresistance

William L. Carroll, MD

Clinical Development of Epigenetic Therapy in Childhood ALL: Reprogramming ALL Blasts to Reverse Chemoresistance

Michael J. Burke, MD

(S07) The Tipping Point: Iron-Restricted Anemias and Iron Overload Disorders

Moderator: Cameron Trenor, MD

Iron-restricted anemias and iron overload disorders affect millions of children. The past decade has produced major advances in the

understanding of these disorders on a molecular basis. In addition, clinical advances in imaging of iron overload, available oral iron chelation options, intravenous iron supplementation, and the discovery of hepcidin as a master regulator of iron homeostasis have changed the approach to these patients. Anticytokine and antihepcidin therapies are entering clinical trials. The American Academy of Pediatrics (AAP) recently updated its statement on the diagnosis and prevention of iron deficiency in young children. This symposium will provide an overview of our current understanding of iron absorption, storage, and recycling, and its application to common consultation questions, and will discuss recently updated AAP guidelines, parenteral iron supplementation, quantification of iron overload, and modern approaches to chelation.

Overview of Knowledge Gaps in Iron Homeostasis

Cameron Trenor, MD

Iron in Excess—Quantification and Chelation Strategies

Janet L. Kwiatkowski, MD MSCE

Current Approaches to Iron-Restricted Erythropoiesis

Matthew M. Heeney, MD

Iron Homeostasis—Lessons from Genetic Studies of Mice and Men

Mark D. Fleming, MD DPhil

11:30 am–1 pm

Concurrent Workshops

(W07) Thromboprophylaxis: Who, When, Why, How?

Moderator: Bryce A. Kerlin, MD

Venous thromboembolism (VTE) is an increasingly common complication in pediatric health care and is associated with significant morbidity and mortality. Evidence-based approaches to VTE prevention in children are limited. Appropriate studies designed to provide these data are difficult to design or conduct due to limited case numbers, case distribution among subspecialties, and other factors. Recently, novel approaches, including comprehensive literature review, meta-analyses, and secondary analyses of large data sets, have been utilized to overcome these obstacles. This workshop will provide interactive discussions about these novel approaches and their results. Three speakers will discuss medical thromboprophylaxis, trauma/surgical thromboprophylaxis, and recurrent VTE thromboprophylaxis. Each speaker has a published track record in her or his area and will present a poignant case; discuss his or her approach to the problem, the evidence, and limitations; and provide a discussion of future directions. A moderated interactive discussion session will follow.

Medical Thromboprophylaxis

Leslie Raffini, MD MSCE

Trauma/Surgical Thromboprophylaxis

Sarah O'Brien, MD MSc

Recurrent VTE Thromboprophylaxis

Guy Young, MD

(W08) Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Children Are Not Little Adults

Moderator: Lillian Sung, MD PhD

Clinical practice guidelines help healthcare professionals and patients make decisions related to health, and they may improve the quality of health care. In cancer patients, guidelines are important to facilitating management of febrile neutropenia (FN). Several FN guidelines have been rigorously developed by organizations, including the Infectious Diseases Society of America and the National Comprehensive Cancer Network; unfortunately, none are focused on children with cancer. Important differences are seen between adults and children with cancer that may greatly impact the management of FN, and furthermore, children are not a homogeneous group. Consequently, it is important to develop guidelines specific for pediatric FN. The presentation will illustrate evidence and recommendations related to the initial evaluation and management of pediatric FN and the approach to empiric antifungal therapy for children with prolonged fever.

Treatment of Pediatric Febrile Neutropenia

Lillian Sung, MD PhD

Evaluation of Initial Presentation of Pediatric Febrile Neutropenia

Robert S. Phillips, MA MSci BMBCb

Approach to Empiric Antifungal Therapy

Thomas Lehrnbecher, MD PhD

11:30 am–2 pm

Exhibits Open

1–2 pm

Lunch in Exhibit Hall

2–4 pm

Symposia

(S08) What Is New in Platelets?

Moderator: Jorge DiPaola, MD

Recent discoveries have rocked the platelet world, indicating that the role of platelets goes beyond the formation of the hemostatic plug. At the beginning of the session, Dr. Jorge DiPaola will discuss the discovery of new genes involved in platelet disorders. It has also been recently reported by Dr. Andrew Weyrich's lab that platelets not only have a vast repertoire of RNAs but also possess an active spliceosome that allows platelets to selectively express proteins. Dr. Weyrich will discuss the molecular basis for this observation as well as its potential role in thrombosis and inflammation. Dr. Martha Sola-Visner will discuss the uniqueness of neonatal megakaryopoiesis and its effect on neonatal platelet function. Finally, Dr. Mortimer Poncz will describe the use of coagulation factor VIII-expressing platelets for the treatment of patients with hemophilia and inhibitors.

The Discovery of New Genes Involved in Platelet Disorders

Jorge DiPaola, MD

Neonatal Platelets: Are They Any Different?

Martha C. Sola-Visner, MD

New Function of Platelets in Thrombosis and Inflammation

Andrew S. Weyrich, PhD

Platelets as Therapeutic Agents in Hemophilia

Mortimer Poncz, MD

(S09) Current Concepts in Ependymoma: From Biology to Clinical Care

Moderator: Donald W. Parsons, MD PhD

Treatment of children with ependymoma is a challenging problem for pediatric oncologists due to the significant morbidity and mortality caused by these tumors. Optimal multimodal management of these patients requires a coordinated effort involving neurosurgeons, radiation oncologists, oncologists, and other critical members of the neuro-oncology team. Recent research efforts have shed light on both the biology of ependymoma and the clinical care of these patients. This symposium will review recent advances in both basic and clinical ependymoma research and provide a multispecialty perspective on the care of children with ependymoma. Presentations will focus on (1) current multidisciplinary approaches to the clinical care of patients with ependymoma, including review of recent ependymoma clinical trials; (2) advances in the biology of ependymoma, with a focus on new information provided by genomic analyses; and (3) novel approaches to risk stratification and treatment of ependymoma based upon emerging biological and translational data.

Surgical Approaches to Ependymoma

Jeffrey H. Wisoff, MD

Multimodal Management of Ependymoma: Efficacy, Toxicity, and Plans for the Future

Thomas E. Merchant, DO PhD

Advances in Ependymoma Biology: Implications for Diagnosis, Risk Stratification, and Therapy

Ching Lau, MD PhD

4:15–6:15 pm

Business Meeting and Award Presentation

- ◆ President's Remarks
- ◆ Frank A. Oski Memorial Lecture
- ◆ Distinguished Career Award

6:15–7:15 pm

Author-Attended Poster Session B

Even-numbered posters

6:15–7:30 pm

Reception with Exhibits and Posters

7:45–8:45 pm

25th Annual Meeting Anniversary Session

Program to be announced

Saturday, May 12

7–8 am

Continental Breakfast

8–9 am

Concurrent Platform Sessions II

9:15–11:15 am

Symposia

(S10) Rare Cancers in Children and Adolescents

Moderator: Leo Mascarenbas, MD MS

Pediatric cancers are rare and constitute <5% of all malignancies. Leukemias and brain tumors make up approximately 50% of all childhood malignancies while the remaining represent a variety of solid tumors. Approximately 10% of these solid tumors are considered very rare in pediatrics, with less than 50 cases each diagnosed every year. These may be adult-type cancers that occur occasionally in the pediatric age group or unique pediatric malignancies. No pediatric standards for the management of these patients exist; pediatric oncologists are often uncomfortable managing these patients because most are exposed to a single patient with one of these diagnoses every 1–2 years. This gap is identified yearly in almost all ASPHO membership surveys, and education on this topic is sought repeatedly. Experts will discuss three rare pediatric malignancies in depth during this symposium and provide evidence-based guidelines on the management of these patients.

Introduction

Leo Mascarenbas, MD MS

Pleuropulmonary Blastoma—A Unique Pediatric Malignancy

Yoav Messinger, MD

Biology and Treatment of Adrenocortical Carcinoma

Gary D. Hammer, MD PhD

Pediatric Nasopharyngeal Carcinoma—What We Know and Hope to Learn

Carlos Rodriguez-Galindo, MD

This symposium is supported in part by the Pablove Foundation.

(S11) Bone Marrow Failure: Emerging Clinical and Molecular Themes

Moderator: Allison Bertuch, MD PhD

During the past decade much has been elucidated regarding the molecular pathways underlying inherited bone marrow failure syndromes such as Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome. Views on optimal therapy for these disorders and for acquired severe aplastic anemia have evolved as well. Gaps in the awareness of the underlying pathophysiologies, the laboratory and genetic testing available to aid in diagnosis, and appropriate approaches to treatment negatively affect optimal patient care. The basic, translational, and clinical research findings reviewed in this symposium will have important clinical implications for patient care in terms of evaluation and diagnostic testing, treatment, genetic counseling, and health surveillance.

Telomere Dysfunction-Driven Bone Marrow Failure

Allison Bertuch, MD PhD

Molecular Mechanisms of Disease in Fanconi Anemia

Agata Smogorzewska, MD PhD

Beyond Housekeeping: Ribosomes in Marrow Failure

Akiko Shimamura, MD PhD

Is Immune Suppressive Therapy the Best Option for All Children and Adolescents with Pediatric Acquired Aplastic Anemia? Proposal for a New Treatment Algorithm

Kirk R. Schultz, MD



“This was an excellent meeting of high quality. Keep up the high standards. Good mix of education and state of the art.”

—2011 Meeting Attendee

Posters

The 25th Annual Meeting will feature two author-attended poster sessions. Chosen from a large number of submissions, the posters will represent the best innovations and research in the study and treatment of pediatric hematology/oncology. Poster abstracts selected for presentation at the Annual Meeting will be published online in a searchable PDF and in a *Pediatric Blood & Cancer* journal supplement. This will allow registrants to plan their poster viewing in advance of the meeting. The abstracts are scheduled to be available in April 2012. To search and view the abstracts, visit www.aspho.org.



Faculty

Hisham M. Abdel-Azim, MD

Children's Hospital Los Angeles
Los Angeles, CA

Denise Adams, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Gladstone Airewele, MD MPH

Baylor College of Medicine
Houston, TX

Mary Austin, MD MPH

University of Texas MD Anderson Cancer Center
Houston, TX

Raymond Barnhill, MD

Global Pathology Laboratory
Miami, FL

Alison Bertuch, MD PhD

Baylor College of Medicine
Houston, TX

Amy L. Billett, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Amanda M. Brandow, DO MS

Medical College of Wisconsin
Milwaukee, WI

Patrick Brown, MD

Johns Hopkins Hospital
Baltimore, MD

Michael J. Burke, MD

University of Minnesota Amplatz Children's
Hospital
Minneapolis, MN

Mitchell S. Cairo, MD

New York Medical College
Valhalla, NY

William L. Carroll, MD

New York University Cancer Institute
New York, NY

Murali M. Chintagumpala, MD

Baylor College of Medicine
Houston, TX

Kara Davis, MD

Stanford University School of Medicine
Palo Alto, CA

Jenny M. Despotovic, DO MS

Baylor College of Medicine
Houston, TX

Douglas S. Diekema, MD MPH

Seattle Children's Research Institute
Seattle, WA

Jorge DiPaola, MD

The Children's Hospital, Denver
Aurora, CO

Sinisa Dovat, MD PhD

Penn State Hershey Pediatric
Hershey, PA

Michael A. Dyer, PhD

St. Jude Children's Research Hospital
Memphis, TN

Conrad V. Fernandez, MD FRCP

IWK Health Centre
Halifax, NS, Canada

James Feusner, MD

Children's Hospital of Oakland
Oakland, CA

Lisa Filipovich, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Mark D. Fleming, MD DPhil

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Brenda L. Gallie, MD

University of Toronto
Toronto, ON, Canada

James I. Geller, MD FAAP

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Douglas K. Graham, MD PhD

University of Colorado Denver
Aurora, CO

Gary D. Hammer, MD PhD

University of Michigan
Ann Arbor, MI

Caroline A. Hastings, MD

Children's Hospital of Oakland
Oakland, CA

Matthew M. Heeney, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Joanne M. Hilden, MD

Children's Hospital Denver
Aurora, CO

Dennis P. Hughes, MD PhD

University of Texas MD Anderson Cancer Center
Houston, TX

Shiu-Ki R. Hui, MD

Baylor College of Medicine
Houston, TX

Michael R. Jeng, MD

Stanford University School of Medicine
Palo Alto, CA

Theodore Johnson, MD PhD

Georgia Health Sciences University
Augusta, GA

Rima Jubran, MD

Children's Hospital Los Angeles
Los Angeles, CA

Bryce A. Kerlin, MD

Nationwide Children's Hospital
Columbus, OH

Jennifer C. Kesselheim, MD MED

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Roshni Kulkarni, MD

Michigan State University
East Lansing, MI

Janet L. Kwiatkowski, MD MSCE

Children's Hospital of Philadelphia
Philadelphia, PA

Ching Lau, MD PhD

Baylor College of Medicine
Houston, TX

Thomas Lehrnbecher, MD PhD

University of Frankfurt
Frankfurt, Hessa, Germany

Li-Fraumeni Family

Salt Lake City, UT

Jeffrey M. Lipton, MD PhD

Steven and Alexandra Cohen Children's
Medical Center
New Hyde Park, NY

Leo Mascarenhas, MD MS

Children's Hospital Los Angeles
Los Angeles, CA

Thomas E. Merchant, DO PhD

St. Jude Children's Research Hospital
Memphis, TN

Yoav Messinger, MD

Children's Hospitals and Clinics of Minnesota
Minneapolis, MN

Brigitta U. Mueller, MD MHCM

Baylor College of Medicine
Houston, TX

Erin A. Mundt, MS CGC

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Linn Murphree, MD

The Vision Center at Children's Hospital Los
Angeles
Los Angeles, CA

Fariba Navid, MD

St. Jude Children's Research Hospital
Memphis, TN

Joseph P. Neglia, MD MPH

University of Minnesota
Minneapolis, MN

Kristin Nunez, MS

Duke University School of Medicine
Durham, NC

Sarah O'Brien, MD MSc

The Research Institute at Nationwide
Children's Hospital
Columbus, OH

Betty S. Pace, MD

Georgia Health Sciences University
Augusta, GA

Sung-Yun Pai, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Donald W. Parsons, MD PhD

Baylor College of Medicine
Houston, TX

Kimberly J. Payne, PhD

Loma Linda University School of Medicine
Loma Linda, CA

Robert Phillips, MA MSc BMBCh

University of York, Alcuin College
York, West Yorkshire, United Kingdom

Mortimer Poncz, MD

Children's Hospital of Philadelphia
Philadelphia, PA

Michael A. Pulsipher, MD

Primary Children's Medical Center/University
of Utah
Salt Lake City, UT

Leslie Raffini, MD MSCE

Children's Hospital of Philadelphia
Philadelphia, PA

Emily Riehm Meier, MD

Children's National Medical Center
Washington, DC

John A. Robertson, JD

University of Texas at Austin
Austin, TX

Carlos Rodriguez-Galindo, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Zora R. Rogers, MD

University of Texas Southwestern Medical
Center
Dallas, TX

**Vaskar Saha, MD PhD MKBBS DCH
FRCP FRCPATH**

The University of Manchester
Manchester, Greater Manchester, United
Kingdom

Kathleen M. Sakamoto, MD PhD

Stanford School of Medicine
Palo Alto, CA

Joshua D. Schiffman, MD

University of Utah
Salt Lake City, UT

Kirk R. Schultz, MD

British Columbia Children's Hospital/University
of British Columbia
Vancouver, BC, Canada

Shalini Shenoy, MD

Washington University in St. Louis
St. Louis, MO

Akiko Shimamura, MD PhD

Fred Hutchinson Cancer Research Center
Seattle, WA

Charles A. Sklar, MD

Memorial Sloan-Kettering Cancer Center
New York, NY

Kim Smith-Whitley, MD

Children's Hospital of Philadelphia
Philadelphia, PA

Agata Smogorzewska, MD PhD

The Rockefeller University
New York, NY

Martha C. Sola-Visner, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

John J. Strouse, MD PhD

Johns Hopkins University
Baltimore, MD

Lillian Sung, MD PhD

The Hospital for Sick Children
Toronto, ON, Canada

Alexis A. Thompson, MD MPH

Children's Memorial Hospital
Chicago, IL

Cameron Trenor, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Sarah R. Vaiselbuh, MD

Steven and Alexandra Cohen Children's
Medical Center
New Hyde Park, NY

Alan S. Wayne, MD

National Institutes of Health
Bethesda, MD

Daniel S. Wechsler, MD PhD

Duke University Medical Center
Durham, NC

Andrew S. Weyrich, PhD

University of Utah School of Medicine
Salt Lake City, UT

James A. Whitlock, MD

The Hospital for Sick Children
Toronto, ON, Canada

Jeffrey H. Wisoff, MD

New York University Langone Medical Center
New York, NY

Michael K. Wong, MD PhD FRCP

University of Southern California
Los Angeles, CA

William G. Woods, MD

Aflac Cancer Center and Emory University
Atlanta, GA

Donald L. Yee, MD

Baylor College of Medicine
Houston, TX

Guy Young, MD

Children's Hospital Los Angeles
Los Angeles, CA

Patrick A. Zweidler-McKay, MD PhD

University of Texas MD Anderson Cancer Center
Houston, TX

Corporate Forum Symposium

An independently sponsored corporate forum symposium is being offered in conjunction with the ASPHO 25th Annual Meeting. This program has been reviewed and approved by the 2012 ASPHO Program Committee to ensure that it is relevant to the audience and that it does not duplicate the official ASPHO program.

This satellite symposium is open to registrants of the 2012 Annual Meeting at no additional charge, although preregistration is required. See the registration details for the symposium below. Seating is available on a first-come, first-served basis. Additional satellite programming will be announced as information becomes available.

Thursday, May 10

7:30–9 pm

Corporate Forum Dinner Symposium

Rare Bleeding Disorders: Clinical Presentation, Diagnosis, and Current Therapeutic Interventions

Amy D. Shapiro, MD; Suchitra S. Achary, MD; Diane J. Nugent, MD; Guglielmo Mariani, MD; Flora Peyvandi, MD

Patients with rare bleeding disorders (RBDs) need safe and effective therapy for optimal outcomes. Increased awareness of these RBDs among healthcare providers and harmonized national and international data collections are required as initial steps toward accurate diagnosis, identification of the affected population, and the range of symptoms experienced. Increased efforts toward licensure of specific, safe, and effective therapies are required for improved outcomes. This symposium will help clinicians recognize and classify RBDs, utilize national and international databases and registries, interpret and understand laboratory assays and coagulation tests, develop appropriate treatment plans, and counsel patients and caregivers about potential complications.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians and nurses.

PIM designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Novo Nordisk, Inc.

Please visit us at www.bloodcmecenter.org to learn more about this event. There is no registration fee for attending this symposium; however, seating is limited. To preregister for this symposium, please register online at www.symposiareg.org/aspho or contact Mary Paulson at 847.375.4803. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.



“This was the best ASPHO meeting I have attended. Good balance between clinical application and basic science. Good balance between hematology and oncology.”

—2011 Meeting Attendee

ASPHO Thanks Our 2012 Corporate Members

genzyme

GRIFOLS



Walgreens

ASPHO Thanks the Program Committee

Jorge DiPaola, MD, Chair

The Children's Hospital Denver
Aurora, CO

Douglas K. Graham, MD PhD, Vice Chair

University of Colorado Denver
Aurora, CO

Judith F. Margolin, MD, Past Chair

Baylor College of Medicine
Houston, TX

Denise M. Adams, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Patrick Brown, MD

Johns Hopkins Hospital
Baltimore, MD

Jacqueline N. Casillas, MD MSHS

David Geffen School of Medicine at UCLA
Los Angeles, CA

Sinisa Dovat, MD PhD

Penn State Hershey Pediatric
Hershey, PA

Sumit Gupta, MD

Hospital for Sick Children
Toronto, ON, Canada

Caroline A. Hastings, MD

Children's Hospital of Oakland
Oakland, CA

Leo Mascarenhas, MD MS

Children's Hospital Los Angeles
Los Angeles, CA

Donald W. Parsons, MD PhD

Baylor College of Medicine
Houston, TX

Emily Riehm Meier, MD

Children's National Medical Center
Washington, DC

Cameron Trenor, MD

Dana-Farber Cancer Institute/Children's
Hospital Boston
Boston, MA

Sarah R. Vaiselbuh, MD

Steven and Alexandra Cohen Children's
Medical Center
New Hyde Park, NY

Michael Wang, MD

University of Colorado, Denver
Aurora, CO

Daniel S. Wechsler, MD PhD

Duke University Medical Center
Durham, NC

Donald L. Yee, MD

Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD

Texas Children's Hospital
Houston, TX

Patrick A. Zweidler-McKay, MD PhD

University of Texas MD Anderson Cancer
Center
Houston, TX

Exhibit Schedule

Thursday, May 10

8 am–4 pm Exhibit Setup and Registration
5:45–7:30 pm Opening Reception with Exhibits
and Posters

Friday, May 11

6:30–9:45 am Exhibits Open
6:30–8 am Breakfast in Exhibit Hall
9–9:30 am Break in Exhibit Hall
11:30 am–2 pm Exhibit Hours
1–2 pm Lunch in Exhibit Hall
(sponsored by St. Jude Children's Research
Hospital)
4–7:30 pm Exhibit Hours
4–4:15 pm Break in Exhibit Hall
6:15–7:30 pm Reception in Exhibit Hall
7:30–10 pm Exhibit Teardown

2012 Exhibitors (as of 11/1/2011)

Calmoseptine, Inc.
Children's Hospital Colorado
Cook Children's
Dana-Farber Children's Hospital Cancer Center
Grifols
Novartis Oncology
Octapharma
Sigma Tau Pharmaceuticals, Inc.
St. Jude Children's Research Hospital
Vaxco Pharmaceuticals
Walgreens Infusion Services

ASPHO Thanks the Meeting Supporters



Travel Information

Meeting Location

Hilton New Orleans Riverside
2 Poydras Street
New Orleans, LA 70130

Housing

ASPHO has negotiated a special conference rate at the hotels listed below. To make your reservation, please call and mention that you are attending the ASPHO Meeting or visit the website for online reservations. The negotiated room rates expire on the cutoff dates listed below or when the negotiated room block has been filled. After that time, availability will be limited, and higher rates may apply.

Hilton New Orleans Riverside

2 Poydras Street
New Orleans, LA 70130
Reservations: 800.445.8667
Rate: \$169 single/double
Special Rate Cutoff Date: April 8, 2012
Online Reservations: ASPHOMeeting.org

New Orleans Marriott at the Convention Center

859 Convention Center Boulevard
New Orleans, LA 70130
Reservations: 800.228.9290 or 504.613.2888
Rate: \$249 single/double
Special Rate Cutoff Date: April 17, 2012
Online Reservations: ASPHOMeeting.org

Transportation

For current information regarding airline discounts and ground transportation, please visit ASPHOMeeting.org.



New Orleans

Commonly referred to as a cultural gumbo, New Orleans is a mix of European traditions with Caribbean influences. The preserved French- and Spanish-style architecture and historic streetcars set the atmosphere for exploring the French Quarter, enjoying a café au lait and beignet at the famed Café Du Monde, or listening to a live jazz music performance at Preservation Hall. New Orleans is a city abundant in culture, cuisine, and history, and it's apparent that the city lives by its motto, "Laissez les bons temps rouler!" (let the good times roll). For more information, visit www.neworleanscvb.com.

ASPHO Membership Information


ASPHO is the only organization exclusively for and about pediatric hematology/oncology that fosters collaborations to develop optimal treatments for children with blood disorders and cancer.

Why join ASPHO? The member benefits include

- a member discount of up to \$175 on the annual conference registration fee
- a monthly subscription to *Pediatric Blood & Cancer*, the official journal of ASPHO
- a bimonthly e-newsletter that provides current news and information of interest to members
- career development programming
- occasional webinars targeted to members' interests
- access to the ASPHO Online Member Community, which offers networking opportunities and the ability to share information, documents, links, and files related to optimal treatments and best practices in an organized searchable library
- an annual printed membership directory (in addition to an online directory resource) to help locate and connect with other professionals working in the field of pediatric hematology/oncology
- opportunities for volunteer involvement that contributes to the profession.

ASPHO membership must be endorsed and signed for by a current member of ASPHO in good standing. This signature must be included in Box A of the registration form to complete the registration process.

Trainees must provide a letter of recommendation from their training program director. If you are a Trainee applying for membership, please include this recommendation with your registration form.



ASPHO 2012 Annual Meeting Registration Form

May 9-12, 2012 | New Orleans, LA | Hilton New Orleans Riverside

FOR OFFICE USE ONLY

Cust # _____ Mtg Ord #1- _____

Date _____

Please print. Use a separate form for each registrant. Duplicate as necessary.

Complete Name _____ First Name for Badge _____

Facility _____ Facility City/State _____

Preferred Address (Home Office) _____ City/State/ZIP _____

Home Phone _____ Office Phone _____ Fax _____

E-mail* (required) (Home Office) _____ (FTA) Check here if this will be your first ASPHO Conference.

*You will receive an e-mail confirmation of your registration when it has been processed.

Emergency Contact Name _____ Day Phone _____ Evening Phone _____

To register, make your selections in the boxes below, add the subtotals, and indicate the total amount in Box F.

Conference Registration		A	
	On or before	After	
	3/28/12	3/28/12	
Member Rates			
Regular Member	<input type="checkbox"/> \$475	<input type="checkbox"/> \$560	
Allied Member	<input type="checkbox"/> \$285	<input type="checkbox"/> \$370	
Trainee Member	<input type="checkbox"/> \$165	<input type="checkbox"/> \$250	
Emeritus Member	<input type="checkbox"/> \$200	<input type="checkbox"/> \$285	
Join & Register Rates (add dues in Box B)			
<i>ASPHO membership requires endorsement from a current ASPHO member. This signature must be included below for your registration to be processed. For more information about endorsement or if you are a Trainee, please refer to page 14.</i>			
Active Member	<input type="checkbox"/> \$475	<input type="checkbox"/> \$560	
Allied Member	<input type="checkbox"/> \$285	<input type="checkbox"/> \$370	
Trainee Member	<input type="checkbox"/> \$165	<input type="checkbox"/> \$250	
Member Endorsement (Required to join ASPHO)			
Member Name (please print)	_____		
Member Signature	_____	Date	_____
Nonmember Rates			
Nonmember	<input type="checkbox"/> \$660	<input type="checkbox"/> \$745	
Allied Nonmember	<input type="checkbox"/> \$375	<input type="checkbox"/> \$460	
Trainee Nonmember	<input type="checkbox"/> \$220	<input type="checkbox"/> \$305	
Additional Rates*			
Medical Student	<input type="checkbox"/> \$50	<input type="checkbox"/> \$50	
SIOP Member	<input type="checkbox"/> \$575	<input type="checkbox"/> \$660	
Physician from Developing Country	<input type="checkbox"/> \$200	<input type="checkbox"/> \$200	
<i>*Only available by phone, fax, or mail. Verification will be made before registration is processed.</i>			
Subtotal A \$ _____			

Membership Dues		B	
Active Member	<input type="checkbox"/> \$335	Trainee Member	
Allied Member	<input type="checkbox"/> \$150	First-year fellow	<input type="checkbox"/> no charge
<i>ASPHO membership requires endorsement from a current ASPHO member. This signature must be included in Box A for your registration to be processed. For more information about endorsement or if you are a Trainee, please refer to page 14.</i>			
		Second-year fellow	<input type="checkbox"/> no charge
		Third-year fellow	<input type="checkbox"/> no charge
		Fourth-year fellow	<input type="checkbox"/> \$115
		Fifth-year fellow	<input type="checkbox"/> \$115
Subtotal B \$ _____			

Special Requests	C
<input type="checkbox"/> I will be using a wheelchair at the conference. (SA)	
<input type="checkbox"/> I will need a vegetarian meal. (SDV)	
<input type="checkbox"/> I do not wish to have my name and contact information included in the on-site attendee list. (DIS)	

Photography Disclosure: Photographs may be taken of participants in ASPHO's 2012 Annual Meeting. These photos are for ASPHO use only and may appear on ASPHO's website, in printed brochures, or in other promotional materials. Attendee registration grants ASPHO permission and consent for use of this photography.

Cancellation Policy: All cancellations must be made in writing. A \$100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after April 25, 2012. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions due to low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.

Session Registration		D	
<i>Please note the following workshops you plan to attend. See page 3 for session codes.</i>			
Wednesday, May 9		Friday, May 11	
3-5 pm	<input type="checkbox"/> S <input type="checkbox"/> O <input type="checkbox"/>	7:30-9 am	<input type="checkbox"/> W <input type="checkbox"/> O <input type="checkbox"/>
5:30-7 pm	<input type="checkbox"/> W <input type="checkbox"/> O <input type="checkbox"/>	9:30-11:30 am	<input type="checkbox"/> S <input type="checkbox"/> O <input type="checkbox"/>
Thursday, May 10		11:30 am-1 pm	<input type="checkbox"/> W <input type="checkbox"/> O <input type="checkbox"/>
7:30-9 am	<input type="checkbox"/> W <input type="checkbox"/> O <input type="checkbox"/>	2-4 pm	<input type="checkbox"/> S <input type="checkbox"/> O <input type="checkbox"/>
2:30-4:30 pm	<input type="checkbox"/> S <input type="checkbox"/> O <input type="checkbox"/>	Saturday, May 12	
		9:15-11:15 am	<input type="checkbox"/> S <input type="checkbox"/> O <input type="checkbox"/>

Optional Event Registration		E	
Wednesday, May 9			
<input type="checkbox"/> 7:15-8:45 pm	Division Directors Dinner Meeting (DDM) \$70		
Thursday, May 10			
<input type="checkbox"/> 12:45-2:15 pm	One-on-One Young Investigator Career Workshop Lunch (LO1)* \$15 <i>(Limited to the first 80 registrants)</i>		
Please select one topic for your table assignment:			
<input type="checkbox"/> Basic Science/Translational Research (LBT)	<input type="checkbox"/> Clinical Research: Hematology (LCH)		
<input type="checkbox"/> Clinical Research: Oncology (LCO)	<input type="checkbox"/> Health Services/Late Effects (LCS)		
<input type="checkbox"/> Clinician/Educator (LCE)	<input type="checkbox"/> Foreign Medical Graduates (FMG)		
*Attendance limited to Young Investigators only.			
<input type="checkbox"/> 12:45-2:15 pm	Novel Reduced Toxicity Conditioning Regimens (LO2) <i>(Limited to the first 200 registrants)</i>		
<input type="checkbox"/> 7:30-9 pm	Training Program Directors' Dinner Meeting (PDD)** \$60		
**Attendance limited to Program Directors only.			
<input type="checkbox"/> DVD of conference recording (to ship after the meeting) (DVD) \$45			
Subtotal E \$ _____			

4 Easy Ways to Register	
Mail	ASPHO Meeting PO Box 839 Glenview, IL 60025-0839
Phone*	847.375.4716
Fax*	866.585.0477
Online*	ASPHOMeeting.org
<i>*credit card payment only</i>	

(A + B + E) = \$ _____ **Total F**

Payment	
All funds must be submitted in U.S. dollars.	
<input type="checkbox"/> Visa	<input type="checkbox"/> MasterCard
<input type="checkbox"/> Discover	<input type="checkbox"/> American Express
<input type="checkbox"/> Check	
If payment does not accompany this form, your registration will not be processed.	
<ul style="list-style-type: none"> Make checks payable to ASPHO. Checks not in U.S. funds will be returned. A charge of \$50 will apply to checks returned for insufficient funds. If rebilling of a credit card charge is necessary, a \$75 processing fee will be charged. I authorize ASPHO to charge the above-listed credit card amounts reasonably deemed by ASPHO to be accurate and appropriate. 	
Account number	Exp. date
Cardholder's name (print)	Signature

Reasons for Attending the **25th Annual** ASPHO Meeting

May 9–12, 2012  New Orleans, LA  Hilton New Orleans Riverside



- ◆ 23.25 hours of CME credit are available to attendees.
- ◆ Enjoy the French Quarter with fellow ASPHO members as you indulge in the city's renowned jazz and savory Cajun cuisine.
- ◆ The Hilton New Orleans offers a special conference rate of \$169.
- ◆ With more than 45 museums, colonial landmarks dotting every corner, and some of the best live music in the country, the Crescent City will captivate your imagination and dancing feet.
- ◆ Enjoy the 25th Anniversary Celebration.
- ◆ ASPHO President Jeffrey Lipton will present "Ethical Dilemmas in Pediatric Hematology/Oncology" during the Presidential Symposium.
- ◆ Network with a diverse and experienced faculty.

ASPHOMeeting.org